Monthly Maintenance Doses of Lebrikizumab Produce Long-lasting Results in AD
More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis (AD) who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing, according to long-term results from the ADjoin long-term extension study. The results […]